Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.

PURPOSE To determine whether the administration of histology-tailored neoadjuvant chemotherapy (HT) was superior to the administration of standard anthracycline plus ifosfamide neoadjuvant chemotherapy (A+I) in high-risk soft tissue sarcoma (STS) of an extremity or the trunk wall. PATIENTS AND METHODS This was a randomized, open-label, phase III trial. Patients had localized high-risk STS (grade 3; size, ≥ 5 cm) of an extremity or trunk wall, belonging to one of the following five histologic subtypes: high-grade myxoid liposarcoma (HG-MLPS); leiomyosarcoma (LMS), synovial sarcoma (SS), malignant peripheral nerve sheath tumor (MPNST), and undifferentiated pleomorphic sarcoma (UPS). Patients were randomly assigned in a 1:1 ratio to receive three cycles of A+I or HT. The HT regimens were as follows: trabectedin in HG-MLPS; gemcitabine plus dacarbazine in LMS; high-dose prolonged-infusion ifosfamide in SS; etoposide plus ifosfamide in MPNST; and gemcitabine plus docetaxel in UPS. Primary and secondary end points were disease-free survival (DFS) and overall survival (OS), estimated using the Kaplan-Meier method and compared using Cox models adjusted for treatment and stratification factors. The study is registered at ClinicalTrials.gov (identifier NCT01710176). RESULTS Between May 2011 and May 2016, 287 patients (UPS: n = 97 [33.8%]; HG-MLPS: n = 65 [22.6%]; SS: n = 70 [24.4%]; MPNST: n = 27 [9.4%]; and LMS: n = 28 [9.8%]) were randomly assigned to either A+I or HT. At the final analysis, with a median follow-up of 52 months, the projected DFS and OS probabilities were 0.55 and 0.47 (log-rank P = .323) and 0.76 and 0.66 (log-rank P = .018) at 60 months in the A+I arm and HT arm, respectively. No treatment-related deaths were observed. CONCLUSION In a population of patients with localized high-risk STS, HT was not associated with a better DFS or OS, suggesting that A+I should remain the regimen to choose whenever neoadjuvant chemotherapy is used in patients with high-risk STS.

[1]  J. Blay,et al.  Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups , 2019, EClinicalMedicine.

[2]  S. Litière,et al.  The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. , 2019, European journal of cancer.

[3]  J. Wunder,et al.  Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. , 2018, European journal of cancer.

[4]  S. Sleijfer,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Blay,et al.  Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. , 2017, The Lancet. Oncology.

[6]  A. Llombart‐Bosch,et al.  Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  L. Mariani,et al.  Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. , 2016, The Lancet. Oncology.

[8]  S. Steinberg,et al.  SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). , 2013 .

[9]  A. D. Dei Tos,et al.  Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[11]  A. Llombart‐Bosch,et al.  Tumor response assessment by modified Choi criteria in localized high‐risk soft tissue sarcoma treated with chemotherapy , 2012, Cancer.

[12]  J. Verweij,et al.  Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. , 2012, The Lancet. Oncology.

[13]  J. Maurel,et al.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  V. Torri,et al.  High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. , 2009, Radiology.

[15]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[16]  L. Qin,et al.  A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients , 2008, Clinical Cancer Research.

[17]  F. Farrokhyar,et al.  A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma , 2008, Cancer.

[18]  Robin L. Jones,et al.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. , 2007, The Lancet. Oncology.

[19]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Stuart J Pocock,et al.  Current controversies in data monitoring for clinical trials , 2006, Clinical trials.

[22]  M. Berretta,et al.  Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas , 2003, Oncology.

[23]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Sylvester,et al.  Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997 .

[25]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[27]  D.,et al.  Regression Models and Life-Tables , 2022 .